

Cystinuria Gene Panel, Varies

## Overview

### **Useful For**

Follow up for abnormal biochemical results suggestive of cystinuria

Establishing a molecular diagnosis for patients with cystinuria

Identifying variants within genes known to be associated with cystinuria, allowing for predictive testing of at-risk family members

#### **Reflex Tests**

Test Id	Reporting Name	Available Separately	Always Performed
CULFB	Fibroblast Culture for	Yes	No
	Genetic Test		

#### **Genetics Test Information**

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 3 genes associated with cystinuria: *SLC3A1*, *SLC7A9*, and *PREPL*. See <u>Targeted Genes and Methodology Details for Cystinuria Gene Panel</u> and Method Description for additional details.

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for cystinuria.

#### **Testing Algorithm**

For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

## **Special Instructions**

- Molecular Genetics: Biochemical Disorders Patient Information
- Informed Consent for Genetic Testing
- Blood Spot Collection Card-Spanish Instructions
- Blood Spot Collection Card-Chinese Instructions
- Informed Consent for Genetic Testing (Spanish)
- Blood Spot Collection Instructions
- Targeted Genes and Methodology Details for Cystinuria Gene Panel

#### **Method Name**

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

### **NY State Available**

Yes



Cystinuria Gene Panel, Varies

## Specimen

## **Specimen Type**

Varies

## **Ordering Guidance**

The recommended first-tier test to screen for cystinuria is urinary measurement of cystine, lysine, ornithine, and arginine; order either CYSQN / Cystinuria Profile, Quantitative, 24 Hour, Urine or CYSR / Cystinuria Profile, Quantitative, Random, Urine.

Customization of this panel and single gene analysis for any gene present on this panel is available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

## **Shipping Instructions**

Specimen preferred to arrive within 96 hours of collection.

## **Specimen Required**

**Patient Preparation:** A previous bone marrow transplant from an allogenic donor will interfere with testing. For instructions for testing patients who have received a bone marrow transplant, call 800-533-1710.

#### Submit only 1 of the following specimens:

Specimen Type: Whole blood

Container/Tube: Lavender top (EDTA) or yellow top (ACD)

**Specimen Volume:** 3 mL **Collection Instructions:** 

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. **Do not aliquot**.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated 14 days

Specimen Type: Skin biopsy

Supplies: Fibroblast Biopsy Transport Media (T115)

Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The

solution should be supplemented with 1% penicillin and streptomycin.

Specimen Volume: 4-mm punch

Specimen Stability Information: Refrigerated (preferred)/Ambient

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or

Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.



Cystinuria Gene Panel, Varies

**Specimen Type**: Cultured fibroblast

Container/Tube: T-25 flask Specimen Volume: 2 Flasks

**Collection Instructions**: Submit confluent cultured fibroblast cells from a skin biopsy from another laboratory. Cultured

cells from a prenatal specimen will not be accepted.

**Specimen Stability Information**: Ambient (preferred)/Refrigerated (<24 hours)

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or

Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.

Specimen Type: Blood spot

Supplies: Card-Blood Spot Collection (Filter Paper) (T493)

Container/Tube:

Preferred: Collection card (Whatman Protein Saver 903 Paper)

Acceptable: PerkinElmer 226 (formerly Ahlstrom 226) filter paper, or blood spot collection card

Specimen Volume: 5 Blood spots

**Collection Instructions:** 

- 1. An alternative blood collection option for a patient older than 1 year is a fingerstick. For detailed instructions, see How to Collect Dried Blood Spot Samples.
- 2. Let blood dry on the filter paper at ambient temperature in a horizontal position for a minimum of 3 hours.
- 3. Do not expose specimen to heat or direct sunlight.
- 4. Do not stack wet specimens.
- 5. Keep specimen dry.

Specimen Stability Information: Ambient (preferred)/Refrigerated

#### **Additional Information:**

- 1. Due to lower concentration of DNA yielded from blood spot, it is possible that additional specimen may be required to complete testing.
- 2. For collection instructions, see <u>Blood Spot Collection Instructions</u>
- 3. For collection instructions in Spanish, see <u>Blood Spot Collection Card-Spanish Instructions</u> (T777)
- 4. For collection instructions in Chinese, see Blood Spot Collection Card-Chinese Instructions (T800)

Specimen Type: Saliva

Patient Preparation: Patient should not eat, drink, smoke, or chew gum 30 minutes prior to collection.

**Supplies:** 

DNA Saliva Kit High Yield (T1007) Saliva Swab Collection Kit (T786)

Container/Tube:

Preferred: High-yield DNA saliva kit

Acceptable: Saliva swab

**Specimen Volume**: 1 Tube if using T1007 or 2 swabs if using T786 **Collection Instructions:** Collect and specimen per kit instructions.

Specimen Stability Information: Ambient (preferred) 30 days/Refrigerated 30 days

**Additional Information:** Saliva specimens are acceptable but not recommended. Due to lower quantity/quality of DNA yielded from saliva, some aspects of the test may not perform as well as DNA extracted from a whole blood sample. When applicable, specific gene regions that were unable to be interrogated will be noted in the report. Alternatively, additional specimen may be required to complete testing.



Cystinuria Gene Panel, Varies

#### **Forms**

- 1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:
- -Informed Consent for Genetic Testing (T576)
- -Informed Consent for Genetic Testing (Spanish) (T826)
- 2. Molecular Genetics: Biochemical Disorders Patient Information (T527)
- 3. If not ordering electronically, complete, print, and send a <u>Biochemical Genetics Test Request</u> (T798) with the specimen.

#### **Specimen Minimum Volume**

See Specimen Required

#### Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

## **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

## **Clinical & Interpretive**

## Clinical Information

Cystinuria is an inborn error of metabolism resulting from poor absorption and reabsorption of the amino acid cystine in the intestines and kidneys. This leads to an accumulation of poorly soluble cystine and dibasic amino acids (lysine, arginine, and ornithine) in the urine and results in the production of kidney stones (urolithiasis). Symptoms may include acute episodes of abdominal or lower back pain, presence of blood in the urine (hematuria), and recurrent episodes of kidney stones may result in frequent urinary tract infections, which may ultimately result in renal insufficiency. The combined incidence of cystinuria has been estimated to be 1 in 7000.

Cystinuria is an autosomal recessive disease, but some heterozygous carriers have an autosomal dominant, incomplete penetrance appearance with elevated, but typically benign, urinary cystine and dibasic amino acid excretion. Some heterozygotes do tend to have higher levels of lysine and cystine versus arginine and ornithine as compared to patients with homozygous variants, who excrete large amounts of cysteine and all 3 dibasic amino acids.

Cystinuria is caused by variants in genes, *SLC3A1* and *PREPL* on chromosome 2p and *SLC7A9* on chromosome 19q. Initially, the disease was classified into subtypes I, II, and III (type II and III are also referred as nontype I) based on the amount of urinary cystine excreted in heterozygous parental specimens. A new classification system has been proposed to distinguish the various forms of cystinuria: type A, due to variants in the *SLC3A1* gene; type B, due to variants in the *SLC7A9* gene; and type AB, due to 1 variant in each *SLC3A1* and *SLC7A9* gene.

A contiguous gene deletion involving both *SLC3A1* and *PREPL* gene is associated with an autosomal recessive hypotonia-cystinuria syndrome, presenting with dysmorphic features, severe neonatal hypotonia, myasthenic syndrome, failure to thrive in infancy with transition to hyperphagia in late childhood, and nephrolithiasis with excretion



Cystinuria Gene Panel, Varies

of cystine, lysine, arginine, and ornithine. Variants in the *PREPL* gene are associated with autosomal recessive congenital myasthenic syndrome 22 (CMS22), which does not present with cystinuria.

Urinary measurement of cystine, lysine, ornithine, and arginine (CYSQN / Cystinuria Profile, Quantitative, 24 Hour, Urine or CYSR / Cystinuria Profile, Quantitative, Random, Urine) is recommended as a first-tier test to screen for cystinuria prior to molecular genetics testing.

Treatment/management options for cystinuria include a high fluid intake, alkali and dietary modifications, and administration of oral tiopronin to prevent formation of cystine stones.

#### **Reference Values**

An interpretive report will be provided.

## Interpretation

All detected alterations are evaluated according to American College of Medical Genetics and Genomics recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

## **Cautions**

## **Clinical Correlations:**

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of at least one reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

To discuss the availability of additional testing options or for assistance in the interpretation of these results, contact the Mayo Clinic Laboratories genetic counselors at 800-533-1710.

## **Technical Limitations:**

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.

This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.

Deletion/Duplication Analysis:



Cystinuria Gene Panel, Varies

This analysis targets single and multi-exon deletions/duplications; however, in some instances single exon resolution cannot be achieved due to isolated reduction in sequence coverage or inherent genomic complexity. Balanced structural rearrangements (such as translocations and inversions) may not be detected.

This test is not designed to detect low levels of mosaicism or to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. For detailed information regarding gene-specific performance and technical limitations, see Method Description or contact a laboratory genetic counselor.

If the patient has had an allogeneic hematopoietic stem cell transplant or a recent heterologous blood transfusion, results may be inaccurate due to the presence of donor DNA. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

#### Reclassification of Variants:

Currently, it is not standard practice for the laboratory to systematically review previously classified variants on a regular basis. The laboratory encourages healthcare providers to contact the laboratory at any time to learn how the classification of a particular variant may have changed over time. Due to broadening genetic knowledge, it is possible that the laboratory may discover new information of relevance to the patient. Should that occur, the laboratory may issue an amended report.

## Variant Evaluation:

Evaluation and categorization of variants is performed using published American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations as a guideline.(1) Other gene-specific guidelines may also be considered. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. Variants classified as benign or likely benign are not reported.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and periodic updates to these tools may cause predictions to change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgement.

Rarely, incidental or secondary findings may implicate another predisposition or presence of active disease. These findings will be carefully reviewed to determine whether they will be reported

## **Clinical Reference**

- 1. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424
- 2. Palacín M, Goodyer P, Nunes V, et al: Cystinuria. In: Valle D, Antonarakis S, Ballabio A, Beaudet A, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease: McGraw-Hill; 2019. Accessed January 07, 2020. Available at http://ommbid.mhmedical.com/content.aspx?bookid=2709&sectionid=225555540
- 3. Eggermann T, Spengler S, Venghaus A, et al: 2p21 Deletions in hypotonia-cystinuria syndrome. Eur JMed Genet.



Cystinuria Gene Panel, Varies

2012;55(10)561-563

4. Regal L, Shen XM, Selcen D, et al: PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome. Neurology. 2014;82(14)1254-1260

## **Performance**

## **Method Description**

Next-generation sequencing (NGS) and/or Sanger sequencing is performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated to be over 99% for single nucleotide variants, over 94% for insertions/deletions (indels) less than 40 base pairs (bp), over 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. See <u>Targeted Genes and Methodology Details for Cystinuria Gene Panel</u> for details regarding targeted genes analyzed and the specific gene regions not routinely covered.(Unpublished Mayo method)

Genes analyzed: SLC3A1, SLC7A9, and PREPL.

### **PDF Report**

Supplemental

## Day(s) Performed

Varies

#### Report Available

21 to 28 days

#### **Specimen Retention Time**

Whole blood: 2 weeks (if available); Extracted DNA: 3 months; Blood spots/Saliva:1 month

### **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

## **Fees & Codes**

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.



Cystinuria Gene Panel, Varies

• Prospective clients should contact their account representative. For assistance, contact Customer Service.

## **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

#### **CPT Code Information**

81479

88233-Tissue culture, skin, solid tissue biopsy (if appropriate)

88240-Cryopreservation (if appropriate)

## **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
CYSGP	Cystinuria Gene Panel	105260-4

Result ID	Test Result Name	Result LOINC® Value
608728	Test Description	62364-5
608729	Specimen	31208-2
608730	Source	31208-2
608731	Result Summary	50397-9
608732	Result	82939-0
608733	Interpretation	69047-9
608735	Additional Information	48767-8
608734	Resources	99622-3
608736	Method	85069-3
608737	Genes Analyzed	48018-6
608738	Disclaimer	62364-5
608739	Released By	18771-6